Dechra, a global leader in veterinary specialty care, this week announced the FDA approval ofZygolide (pergolide tablets), the first FDA-approved bioequivalentoptionindicatedfor the control of clinical signs associated with pituitary pars intermedia dysfunction (PPID) in horses.The condition, also known as Equine Cushings Disease,affects approximately 21% of horses aged 15 and older, and prevalence increases to 30% in horses over 30 yearsold.As the population of senior horses continues to grow, the need formore affordabletreatment optionshas become increasingly important for both veterinarians and caretakers2.This approval expands access to anessentialtherapy for one of the most common endocrine disorders in aging horses.Zygolideoffers anenhancedstandard of care for patient experience through:Pill structure:TheZygolidetablet is designed with ease of administration in mind. Its manageable size and shape, along with360-degreescoringon all sides, make it simple to split as needed.Dosing:The Zygolidepackaging is designed to protect tablet stability and ensureaccuratedosing.Flavor profile:With a peppermint flavor,Zygolideprovides anenhancedexperience for horses and their caretakers when administering the medication.Cost:As a genericoption,Zygolideoffers cost relief to horse owners and caretakers, particularly for horsesthatreceive higher doses of treatments for PPID2.The FDA approval ofZygolidebrings to market a high-quality, cost-effective option to helpmakethemanagement ofPPIDmore accessible, saidDr. Greg Schmid, equine medical affairs lead forDechra. This therapy providesanotheroptionfor horses living with the condition, includinga pill structurewith360-degreescoring on all sidesandapeppermintflavor profile, helping to reduce stress for bothhorsesand their caretakers.AvailabilityZygolide(pergolide tablets)will be available throughveterinarians beginning January 2026 andcan bepurchasedwith a prescription from majoronlinepharmaciesnationwide.AboutZygolideZygolide isindicatedfor the control of clinical signs associated with pituitary pars intermedia dysfunction (PPID) (equine Cushings disease) in horses.Zygolideis administered orally.Important Safety InformationAs with all drugs, side effects may occur.Zygolide (pergolide tablets) is for use in horses only.Zygolidehas not been evaluated in breeding,pregnantor lactating horses. Treatment withZygolidemay cause loss of appetite. Most cases are mild. If severe, a temporary dose reduction may be necessary. Weight loss, lack of energy, and behavioral changesalso maybeobserved.Zygolidetablets should not be crushed due to the potential for increased human exposure. Pregnant or lactating women should wear gloves when administering this product.Zygolideis contraindicated in horses with hypersensitivity to pergolide mesylate or other ergot derivatives. KeepZygolidein a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. Dogs have eatenZygolidetablets that were placed in food intended for horses or dropped during administration of the tablets to the horses. Adverse reactions may occur if animals other than horses ingestZygolidetablets. Refer to the prescribing informationhere for complete details or visitwww.dechraus.com.AboutDechraDechrais a global specialist in veterinary pharmaceuticals and related products, dedicated to supporting veterinarians, pet owners, and the animals they care for. For more information, visitwww.dechra-us.com.This product is only available in the US at this time.This communication maycontaininformation otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for you accessing such information that may notcomply withany legal process, regulation, registration,or usage in the country of your origin.ReferencesUniversity of California Davis School of Veterinary Medicine.Pituitary pars intermedia dysfunction (PPID). Davis (CA): UC Davis Center for Equine Health; 2020 Mar 23 . Available from:https://ceh.vetmed.ucdavis.edu/health-topics/pituitary-pars-intermedia-dysfunction-ppidMarket data on file.Dechrais a registered trademark ofDechraPharmaceuticals Limited.Zygolide is a registered trademark ofDechraLimited.